(AOF) – Valbiotis, a Research and Development company committed to scientific innovation, for the prevention and fight against metabolic and cardiovascular diseases, today announces the success of its fundraising for a total amount of 9.7 million euros including, on the one hand, an offer reserved for a category of investors via the accelerated construction of an order book for an amount of approximately 9 million, and on the other hand, an offer to the public intended for individual shareholders via the PrimaryBid platform for an amount of approximately 0.7 million (the “Global Offering”).
As a reminder, the proceeds of the Global Offering will be devoted to financing up to 60%, the structuring of the company to support future global or regional license and/or distribution partnerships (France excepted) on the other TOTUMs of the pipeline (TOTUM 070 – LDL hypercholesterolemia, TOTUM 448 – NAFL/NASH and TOTUM 854 – high blood pressure) and support the already signed licensing and supply agreements of TOTUM 63 (prediabetes)
The global offer will also be devoted to the financing, also up to 40%, of the implementation of resources dedicated to the direct marketing in France of TOTUMs (excluding TOTUM 63).
The Global Offer has been made in particular for the benefit of investment companies and investment funds under French or foreign law (investing or having invested over the past five years in the sector of prevention and/or the fight against chronic diseases) and also for the benefit of member companies of an industrial group governed by French or foreign law (having an activity similar to that of the Company in the fields of prevention and/or the fight against chronic diseases).
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.